Optimizing the Care of Metastatic Colorectal Cancer Patients with Antiangiogenic Agents

An educational symposium held during the 2013 ASCO Annual Meeting. Not an official event of the 2013 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation

Join us Friday evening, May 31 at 6:00pm, in Chicago for Optimizing the Care of Metastatic Colorectal Cancer Patients with Antiangiogenic Agents, a complimentary educational symposium held during the 2013 ASCO Annual Meeting.

As new agents are developed and standards of care change for CRC patients, it becomes imperative that physicians stay abreast of the current practices, updates to treatment recommendations, and have an understanding of the potential benefits and risks of the new therapies to be able to optimally integrate those strategies into clinical practice.

Participants will gain an increased knowledge regarding:

• The angiogenesis pathway in colorectal cancer (CRC) and the different antiangiogenic strategies in clinical development for CRC patient
• The latest clinical data with currently approved and emerging antiangiogenic agent regimens for treatment of mCRC
• Optimizing treatment selection and duration of therapy for the management of progressive disease

Registration

Registration is complimentary. Please remember to bring your ASCO Badge. Space is limited and available on a first come first serve basis.

May 31, 2013
6:00 - 8:30 pm
The Westin Michigan Avenue - Michigan Ballroom (2nd floor)
Chicago, Illinois, USA

Available seating will be based on room capacity. Seating is limited and pre-registration does not guarantee admission, as room may be overbooked. Early arrival is recommended and seating will be first come first serve until capacity is met.

Faculty

Heinz-Josef Lenz, MD
USC Norris Comprehensive Cancer Center
Keck School of Medicine
Los Angeles, California

John L. Marshall, MD
Georgetown University Medical Center
Washington, District of Columbia

Wells A. Messersmith, MD, FACP
University of Colorado Cancer Center
Aurora, Colorado

Eric Van Cutsem, MD, PhD
University Hospitals Leuven
Leuven, Belgium

Agenda

Friday, May 31, 2013

6:00 pm

Registration and dinner

6:30 pm

Welcome and introduction
John L. Marshall, MD

6:35 pm

Pre-activity survey via ARS
John L. Marshall, MD

6:45 pm

Improving patient outcomes by targeting the VEGF/VEGFR axis
Wells A. Messersmith, MD

7:05 pm

Antiangiogenic agents in mCRC: Current treatment options and future directions
Eric Van Cutsem, MD, PhD

7:30 pm

Treatment beyond progression – Is there a new standard of care?
Heinz-Josef Lenz, MD

7:50 pm

Management of mCRC: How do you optimize treatment across multiple lines of therapy?
John L. Marshall, MD

8:15 pm

Q&A and post-activity survey via ARS

8:30 pm

Closing notes and adjourn
John L. Marshall, MD

Continuing Medical Education

Imedex^®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex^®, LLC designates this live educational activity for a maximum 2.0 of AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Who Should Attend

This educational activity is specifically designed for medical oncologists, gastroenterologists, oncology nurses, nurse practitioners, pharmacists, physicians' assistants, researchers, and other healthcare professionals interested and/or involved in the care and treatment of patients with colorectal cancer.

Objectives

After successful completion of this course, participants should be able to:

• Have increased knowledge regarding
  • The angiogenesis pathway in colorectal cancer (CRC) and the different antiangiogenic strategies in clinical development for CRC patients
  • The latest clinical data with currently approved and emerging antiangiogenic agent regimens for treatment of mCRC
• Have increased knowledge regarding
  • Optimize treatment selection and duration of therapy for the management of progressive disease
  • Counsel patients with recurrent disease on appropriate sequencing of antiangiogenic agents based on the clinical impact of the different management strategies

Symposium Location

The Westin Michigan Avenue
909 North Michigan Avenue, Chicago, IL 60611
T (312) 943-7200
F (312) 397-5580
www.westin.com/michiganave
Michigan Ballroom (2nd floor)

The Symposium Information Desk in the Michigan Ballroom Foyer will be staffed:

Friday, May 31, 2013

6:00pm-8:30pm

Don’t forget to bring your laptop or tablet

All slide presentations will be available to view at the event on the electronic device of your choice—laptop, tablet, smart phone, etc., via Array technology*. This is the most convenient way to provide attendees with the most up-to-date information. A book of printed presentations will not be available; we encourage you to use your electronic device during the conference for optimal participation.

Support

The following companies have provided an educational grant in support of this symposium:

Organizer

11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Twitter: twitter.com/ImedexCME
Facebook: facebook.com/Imedex
Web: www.imedex.com